NCT06160323Recruiting
Upfront EUS CGN/CPN vs Conventional Step up Approach for Inoperable Painful Pancreatic Cancer
Upfront Endoscopic Ultrasound-guided Celiac Ganglion Neurolysis Versus Conventional Step-up Approach for Patients With Painful, Inoperable Pancreatic Cancer
Source: ClinicalTrials.gov · Last updated 6 May 2026
Brief summary (registry, in English)
Patients with unresectable pancreatic cancer are often demoralized by intractable, persistent and incapacitating pain. It must be managed aggressively and strong opioids are recommended as the mainstay of treatment. However, patients develop opioid-related adverse effects. EUS-guided celiac plexus neurolysis (CPN) and celiac ganglion neurolysis (CGN) has been shown to provide high efficacy for pain control. The optimal timing, however, is in debate.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 94 (estimated)
- First submitted
- 29 Nov 2023
- Start date
- 10 Nov 2023
- Primary completion date
- 31 Jul 2027
- Lead sponsor
- Chinese University of Hong Kong
- Diseases
- Pancreatic cancer
- NCT number
- NCT06160323
What you commit to
- Study type: Interventional
- Planned participants: 94
- From 10 Nov 2023 to the primary completion date, 31 Jul 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Potentially operable after neoadjuvant therapy
- Previous percutaneous or EUS-guided CGN/ CPN
Other illness
- Allergy to bupivacaine, or alcohol
Other
- Expected survival of less than 3 months
- Patient who is already on opioids for pain control
- Recurrent pancreatic tumors after operation
- Uncorrectable coagulopathy
- Inability or unwillingness to provide informed consent
Who the study is looking for
- Age \>= 18 years old
- Diagnosed to have inoperable pancreatic cancer
- Presence of tumor pain (centrally located, constant, with no other obvious cause) with a VAS \>= 3
- Karnofsky performance status \>= 60
- Planned for EUS examination and/or biopsy of the pancreatic tumor
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Prince of Wales Hospital Coordinator of this site? Confirm its status | Hong Kong | Hong Kong SAR China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.